AWH (Aspira Womens Health) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health ROE % Adjusted to Book Value?

Aspira Womens Health's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Aspira Womens Health's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Aspira Womens Health's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Aspira Womens Health ROE % Adjusted to Book Value Historical Data

The historical data trend for Aspira Womens Health's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health ROE % Adjusted to Book Value Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-21.26

-2.69

-24.12

-27.08

Aspira Womens Health Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aspira Womens Health's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Aspira Womens Health's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's ROE % Adjusted to Book Value falls into.

Aspira Womens Health ROE % Adjusted to Book Value Calculation

Aspira Womens Health's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-723.45%	/	N/A
	=	N/A

Aspira Womens Health's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Aspira Womens Health ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

IDXG MYNZ TTOO PMD STRR PRPO XWEL APDN PRPH BIAF TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

CUL:Germany

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Executives

Nicole Sandford	director	12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant	officer: General Counsel & Secretary	1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck	officer: Chief Financial Officer	529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick	director	2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh	director	1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan	officer: CSO & COO	327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk	director	6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell	director	6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan	officer: Interim Chief Financial Office	400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma	director	24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach	director	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri	director, officer: President and CEO	63 INDIAN LEDGE RD., MONROE CT 06468